Doximity Announces Fiscal 2022 Third Quarter Financial Results

Rhea-AI Summary

Doximity, Inc. (DOCS) reported a strong fiscal Q3 with revenue of $97.9 million, up 67% year-over-year. The company achieved a net income of $55.6 million with a net income margin of 57%. Key performance metrics included a 171% net revenue retention rate and an adjusted EBITDA of $47.0 million, growing 119% year-over-year. Doximity announced plans to acquire Amion, enhancing its offerings. Future guidance includes Q4 revenue between $89 million and $90 million, and for FY 2023, anticipated revenue growth of 33% to around $450 million.

Positive

• Revenue increased by 67% year-over-year to $97.9 million.
• Net income rose to $55.6 million, reflecting a 57% margin.
• Adjusted EBITDA increased by 119% year-over-year to $47.0 million, with 48% margins.
• Net revenue retention rate reached 171%.
• Doximity's telehealth platform grew to 350,000 active providers.

Negative

• Guidance for Q4 revenue is relatively lower than Q3 performance at $89-$90 million.
• Overall growth may be impacted by the Amion acquisition costs.

SAN FRANCISCO, Feb. 8, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results for the fiscal 2022 third quarter ended December 31, 2021.

"We had a strong Q3 led by our existing clients as our net revenue retention rate hit 171%," said Jeff Tangney, co-founder & CEO at Doximity. "Our telehealth platform grew to 350,000 active providers and we agreed to acquire Amion which powers nearly 200,000 physician schedules. It's our life's work to build the physician cloud – a digital platform to help physicians save time, so they can provide better care for patients."

Doximity Acquiring Amion: More information can be found in the press release at https://investors.doximity.com.

Fiscal 2022 Third Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended December 31, 2020.

• Revenue: Revenue of $97.9 million, versus $58.7 million, an increase of 67% year-over-year.
• Net income and non-GAAP net income: Net income of $55.6 million, versus $17.2 million, representing a 57% margin. Non-GAAP net income of $63.6 million, versus $19.5 million, representing a 65% margin.
• Adjusted EBITDA: Adjusted EBITDA of $47.0 million, versus $21.5 million, an increase of 119% year-over-year, representing adjusted EBITDA margins of 48%, versus 37%.
• Net income per share and non-GAAP net income per share: Diluted net income per share was $0.26, versus $0.05, while non-GAAP diluted net income per share was $0.29, versus $0.07.
• Operating cash flow and free cash flow: Operating cash flow of $27.3 million, versus $24.0 million, and free cash flow of $25.6 million, versus $22.9 million.

Financial Outlook

Doximity is providing guidance for its fiscal fourth quarter ending March 31, 2022 as follows:

• Revenue between $89.0 million and $90.0 million.
• Adjusted EBITDA between $34.0 million and $35.0 million.

Doximity is updating guidance for its fiscal year ending March 31, 2022 as follows:

• Revenue between $338.9 million and $339.9 million.
• Adjusted EBITDA between $144.9 million and $145.9 million.

Doximity is providing preliminary guidance for its fiscal year ending March 31, 2023 as follows:

• Revenue growth of about 33% (excluding the Amion acquisition) to approximately $450 million.
• Adjusted EBITDA margin of 40% or greater (excluding the Amion acquisition).

Conference Call Information

Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company's Investor Relations page shortly after the call.

About Doximity

Founded in 2010, Doximity is the leading digital platform for medical professionals. The company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. For more information, please visit www.doximity.com.

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made.  Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved.  Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the impact of the COVID-19 pandemic (including the impact to our industry or on our customers' industries, impact on general economic conditions, and government responses, restrictions, and actions related to the pandemic); (ii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iii) our ability to attract new customers or retain existing customers; (iv) the impact of our prioritization of our members' interests; (v) breaches in our security measures or unauthorized access to members' data; (vi) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled "Risk Factors" in the prospectus for our recent offering of shares of Class A common stock shares that was filed with the SEC on June 25, 2021, and in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, as such risk factors may be updated from time to time in our periodic filings with the SEC. Additional information will be provided in our Quarterly Report on Form 10-Q for the  quarterly period ended December 31, 2021. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management's beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:
Perry Gold
ir@doximity.com

Media Contact:
pr@doximity.com

DOXIMITY, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
	December 31, 2021		March 31, 2021
Assets
Current assets:
Cash and cash equivalents	$                      85,079		$                      66,393
Marketable securities	680,499		76,141
Accounts receivable, net	69,823		50,319
Prepaid expenses and other current assets	17,917		10,692
Deferred contract costs, current	5,060		5,856
Total current assets	858,378		209,401
Property and equipment, net	8,221		7,598
Deferred income tax assets	35,431		2,112
Operating lease right-of-use assets	1,589		1,339
Intangible assets, net	8,802		9,596
Goodwill	18,915		18,915
Other assets	836		2,758
Total assets	$                    932,172		$                    251,719
Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity
Current liabilities:
Accounts payable	$                        1,230		$                        1,515
Accrued expenses and other current liabilities	23,980		16,285
Deferred revenue, current	65,576		83,272
Operating lease liabilities, current	927		970
Total current liabilities	91,713		102,042
Deferred revenue, non-current	38		220
Operating lease liabilities, non-current	668		284
Other liabilities, non-current	905		972
Total liabilities	93,324		103,518
Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock	—		81,458
Stockholders' Equity
Preferred stock	—		—
Common stock	190		83
Additional paid-in capital	688,290		30,357
Accumulated other comprehensive loss	(4,013)		(21)
Retained earnings	154,381		36,324
Total stockholders' equity	838,848		66,743
Total liabilities, redeemable convertible preferred stock, and stockholders' equity	$                    932,172		$                    251,719

 

DOXIMITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
	Three Months Ended December 31,				Nine Months Ended December 31,
	2021		2020		2021		2020
Revenue	$          97,876		$          58,709		$        249,895		$        140,210
Cost of revenue(1)	11,085		7,872		28,022		23,203
Gross profit	86,791		50,837		221,873		117,007
Operating expenses(1):
Research and development	16,225		11,406		44,926		31,315
Sales and marketing	25,698		17,017		66,230		44,447
General and administrative	9,079		4,478		25,102		10,789
Total operating expenses	51,002		32,901		136,258		86,551
Income from operations	35,789		17,936		85,615		30,456
Other income, net	20		4,601		485		4,428
Income before income taxes	35,809		22,537		86,100		34,884
Provision for (benefit from) income taxes	(19,838)		5,306		(31,957)		6,157
Net income	$          55,647		$          17,231		$        118,057		$          28,727
Undistributed earnings attributable to participating securities	—		(11,831)		(21,866)		(17,907)
Net income attributable to Class A and Class B common stockholders, basic and diluted	$          55,647		$            5,400		$          96,191		$          10,820
Net income per share attributable to Class A and Class B common stockholders:
Basic	$               0.30		$               0.07		$               0.62		$               0.15
Diluted	$               0.26		$               0.05		$               0.53		$               0.12
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:
Basic	188,372		77,766		154,289		72,590
Diluted	216,396		99,923		182,905		92,286

(1) Costs and expenses include share-based compensation expenses as follows:

	Three Months Ended December 31,				Nine Months Ended December 31,
	2021		2020		2021		2020
Cost of revenue	$            1,912		$                179		$            2,973		$                368
Research and development	2,035		634		4,864		1,179
Sales and marketing	2,681		633		5,575		1,304
General and administrative	3,206		774		8,221		1,531
Total stock-based compensation expense	$            9,834		$            2,220		$          21,633		$            4,382

 

DOXIMITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
	Three Months Ended December 31,				Nine Months Ended December 31,
	2021		2020		2021		2020
Cash flows from operating activities
Net income	$        55,647		$        17,231		$      118,057		$        28,727
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	1,361		1,015		3,672		2,711
Deferred income taxes	(31,972)		3,450		(31,972)		4,073
Stock-based compensation, net of amounts capitalized	9,834		2,220		21,633		4,382
Other	642		(287)		570		(182)
Non-cash lease expense	288		718		857		2,012
Bad debt expense (recovery)	(120)		(47)		75		(43)
Amortization of premium on marketable securities, net	1,302		44		2,863		58
Gain on sale of business	—		(4,698)		—		(4,698)
Amortization of deferred contract costs	1,710		1,557		7,366		4,697
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable	(14,021)		403		(19,579)		(14,487)
Prepaid expenses and other assets	10,722		(596)		(7,003)		167
Deferred contract costs	(3,697)		(3,215)		(6,672)		(5,970)
Accounts payable	453		(658)		162		(933)
Accrued expenses and other current liabilities	8,417		6,155		7,998		5,512
Deferred revenue	(13,111)		830		(17,538)		19,373
Operating lease liabilities	(173)		(730)		(811)		(2,040)
Other liabilities	2		569		(67)		2,063
Net cash provided by operating activities	27,284		23,961		79,611		45,422
Cash flows from investing activities
Purchases of property and equipment	(611)		(6)		(852)		(98)
Capitalized internal-use software	(1,065)		(1,069)		(2,736)		(3,599)
Purchases of marketable securities	(115,772)		(34,399)		(1,271,915)		(34,399)
Maturities of marketable securities	6,066		4,000		41,617		38,000
Sales of marketable securities	85,862		—		616,938		—
Cash paid for acquisition, net of cash acquired	—		(48)		—		(31,682)
Other	—		25		—		—
Proceeds from sale of business	—		4,230		—		4,230
Net cash used in investing  activities	(25,520)		(27,267)		(616,948)		(27,548)
Cash flows from financing activities
Proceeds from issuance of common stock upon initial public offering after deducting underwriting discounts and commissions	—		—		553,905		—
Payments of deferred offering costs	—		(381)		(3,982)		(381)
Proceeds from issuance of common stock upon exercise of stock options	4,174		3,075		9,234		4,422
Taxes paid related to net share settlement of equity awards	(380)		—		(436)		—
Repurchase of common stock	—		(370)		(2,698)		(370)
Net cash provided by financing activities	3,794		2,324		556,023		3,671
Net increase (decrease) in cash and cash equivalents	5,558		(982)		18,686		21,545
Cash and cash equivalents, beginning of period	79,521		70,957		66,393		48,430
Cash and cash equivalents, end of period	$        85,079		$        69,975		$        85,079		$        69,975

Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance:

• Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of stock-based compensation expense, amortization of acquired intangible assets, and expenses associated with acquisitions from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
• Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, and other income, net. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
• Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and capitalized internal-use software development cost.

We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Business Metrics

• Net revenue retention rate: We calculate net revenue retention rate by taking the trailing 12-month ("TTM") subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn.
• Customers with trailing 12-month subscription revenue greater than $100,000: We calculate the number of customers with TTM product revenue greater than $100,000 by counting the number of customers that contributed more than $100,000 in subscription revenue in the TTM period. The number of customers with TTM subscription-based revenue of at least $100,000 is a key indicator of the scale of our business. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity.

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

	Three Months Ended December 31,				Nine Months Ended December 31,
	2021		2020		2021		2020
	(unaudited)
	(in thousands)
Net income	$   55,647		$   17,231		$ 118,057		$   28,727
Adjusted to exclude the following:
Acquisition and other related expenses	—		326		—		470
Stock-based compensation	9,834		2,220		21,633		4,382
Depreciation and amortization	1,361		1,015		3,672		2,711
Provision for (benefit from) income taxes	(19,838)		5,306		(31,957)		6,157
Other income, net	(20)		(4,601)		(485)		(4,428)
Adjusted EBITDA	$   46,984		$   21,497		$ 110,920		$   38,019
Revenue	$   97,876		$   58,709		$ 249,895		$ 140,210
Net income margin	57     %		29     %		47     %		20     %
Adjusted EBITDA margin	48     %		37     %		44     %		27     %

 

	Three Months Ended December 31,				Nine Months Ended December 31,
	2021		2020		2021		2020
	(unaudited)
	(in thousands)
Net cash provided by operating activities	$       27,284		$       23,961		$       79,611		$       45,422
Purchases of property and equipment	(611)		(6)		(852)		(98)
Capitalized internal-use software	(1,065)		(1,069)		(2,736)		(3,599)
Free cash flow	$       25,608		$       22,886		$       76,023		$       41,725
Other cash flow components:
Net cash used in investing activities	$     (25,520)		$     (27,267)		$   (616,948)		$     (27,548)
Net cash provided by financing activities	$         3,794		$         2,324		$     556,023		$         3,671

 

	Three Months Ended December 31,				Nine Months Ended December 31,
	2021		2020		2021		2020
	(unaudited)
	(in thousands, except percentages)
GAAP cost of revenue	$   11,085		$     7,872		$   28,022		$   23,203
Adjusted to exclude the following:
Stock-based compensation	(1,912)		(179)		(2,973)		(368)
Non-GAAP cost of revenue	$     9,173		$     7,693		$   25,049		$   22,835
GAAP gross profit	$   86,791		$   50,837		$ 221,873		$ 117,007
Adjusted to exclude the following:
Stock-based compensation	1,912		179		2,973		368
Non-GAAP gross profit	$   88,703		$   51,016		$ 224,846		$ 117,375
GAAP gross margin	89     %		87     %		89     %		83     %
Non-GAAP gross margin	91     %		87     %		90     %		84     %
GAAP research and development expense	$   16,225		$   11,406		$   44,926		$   31,315
Adjusted to exclude the following:
Stock-based compensation	(2,035)		(634)		(4,864)		(1,179)
Non-GAAP research and development expense	$   14,190		$   10,772		$   40,062		$   30,136
GAAP sales and marketing expense	$   25,698		$   17,017		$   66,230		$   44,447
Adjusted to exclude the following:
Stock-based compensation	(2,681)		(633)		(5,575)		(1,304)
Amortization of acquired intangibles	(265)		(303)		(795)		(817)
Non-GAAP sales and marketing expense	$   22,752		$   16,081		$   59,860		$   42,326
GAAP general and administrative expense	$     9,079		$     4,478		$   25,102		$   10,789
Adjusted to exclude the following:
Acquisition and other related expenses	—		(326)		—		(470)
Stock-based compensation	(3,206)		(774)		(8,221)		(1,531)
Non-GAAP general and administrative expense	$     5,873		$     3,378		$   16,881		$     8,788
GAAP operating expense	$   51,002		$   32,901		$ 136,258		$   86,551
Adjusted to exclude the following:
Acquisition and other related expenses	—		(326)		—		(470)
Stock-based compensation	(7,922)		(2,041)		(18,660)		(4,014)
Amortization of acquired intangibles	(265)		(303)		(795)		(817)
Non-GAAP operating expense	$   42,815		$   30,231		$ 116,803		$   81,250
GAAP operating income	$   35,789		$   17,936		$   85,615		$   30,456
Adjusted to exclude the following:
Acquisition and other related expenses	—		326		—		470
Stock-based compensation	9,834		2,220		21,633		4,382
Amortization of acquired intangibles	265		303		795		817
Non-GAAP operating income	$   45,888		$   20,785		$ 108,043		$   36,125

 

	Three Months Ended December 31,				Nine Months Ended December 31,
	2021		2020		2021		2020
	(unaudited)
	(in thousands, except per share data and percentages)
GAAP net income	$  55,647		$  17,231		$  118,057		$  28,727
Adjusted to exclude the following:
Acquisition and other related expenses	—		326		—		470
Stock-based compensation	9,834		2,220		21,633		4,382
Amortization of acquired intangibles	265		303		795		817
Income tax effect of non-GAAP adjustments (1)	(2,121)		(598)		(4,710)		(1,190)
Non-GAAP net income	$  63,625		$  19,482		$  135,775		$  33,206
Non-GAAP net income margin	65     %		33     %		54     %		24     %
GAAP undistributed earnings attributable to participating securities	$          —		$ (11,831)		$ (21,866)		$ (17,907)
Impact on undistributed earnings attributable to participating securities due to non-GAAP adjustments	—		(1,114)		(2,436)		(2,295)
Non-GAAP undistributed earnings attributable to participating securities	$          —		$ (12,945)		$ (24,302)		$ (20,202)
Non-GAAP net income	$  63,625		$  19,482		$  135,775		$  33,206
Non-GAAP undistributed earnings attributable to participating securities	—		(12,945)		(24,302)		(20,202)
Non-GAAP net income attributable to Class A and Class B stockholders, basic and diluted	$  63,625		$     6,537		$  111,473		$  13,004
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:
Basic	188,372		77,766		154,289		72,590
Diluted	216,396		99,923		182,905		92,286
Non-GAAP net income per share attributable to Class A and Class B stockholders:
Basic	$       0.34		$       0.08		$       0.72		$       0.18
Diluted	$       0.29		$       0.07		$       0.61		$       0.14

(1) For the three and nine months ended December 31, 2021 and 2020, management used an estimated annual effective non-GAAP tax rate of 21.0%.

 

View original content:https://www.prnewswire.com/news-releases/doximity-announces-fiscal-2022-third-quarter-financial-results-301477814.html

SOURCE Doximity, Inc.

FAQ

What were Doximity's Q3 earnings results for fiscal 2022?

Doximity reported Q3 revenue of $97.9 million, a 67% increase year-over-year, with a net income of $55.6 million.

What is Doximity's guidance for Q4 fiscal 2022?

Doximity expects Q4 revenue between $89 million and $90 million.

What revenue growth does Doximity anticipate for fiscal year 2023?

Doximity anticipates approximately 33% revenue growth in fiscal year 2023, excluding the Amion acquisition.

How did Doximity's adjusted EBITDA perform in Q3 fiscal 2022?

Adjusted EBITDA for Q3 was $47.0 million, showing a 119% year-over-year increase.

What are the key highlights from Doximity's acquisition of Amion?

Doximity's acquisition of Amion is expected to enhance its platform, which currently supports nearly 200,000 physician schedules.